Soquelitinib inhibition of IL-2-inducible T cell kinase ameliorates lung damage in murine models of systemic sclerosis
Gonçalo Boleto, Anne Cauvet, Christophe Guignabert, Raphaël Thuillet, Mina Ottaviani, Ly Tu, Lih-Yun Hsu, James T. Rosenbaum, Richard A. Miller, Yannick Allanore · 2025
Read Soquelitinib inhibition of IL-2-inducible T cell kinase ameliorates lung damage in murine models of systemic sclerosis by Gonçalo Boleto, Anne Cauvet, Christophe Guignabert, Raphaël Thuillet, Mina Ottaviani, Ly Tu, Lih-Yun Hsu, James T. Rosenbaum, Richard A. Miller, Yannick Allanore (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12729254.txt.
Description
Goncalo Boleto and nine co-authors tested a targeted drug in mouse models of a scarring disease in a 2025 study. Systemic sclerosis stiffens skin and organs, and lung damage is its deadliest part. Overactive T cells drive the early inflammation. The drug blocks a switch inside T cells that helps turn them on.
In one model, a chemical injures the lungs and causes scarring. The drug cut immune cell inflow and eased tissue damage, mainly by calming two T cell branches, though stored collagen did not change. In a second model that also develops high lung blood pressure, the drug improved health scores, tissue scores, and the pressure problem. Signals from one T cell branch fell in the lungs. The authors read the results as support for testing this drug class in the human disease.
Catalog record
| CREATOR | Gonçalo Boleto, Anne Cauvet, Christophe Guignabert, Raphaël Thuillet, Mina Ottaviani, Ly Tu, Lih-Yun Hsu, James T. Rosenbaum, Richard A. Miller, Yannick Allanore |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |